ReceptivaDxTM is a new and improved test for endometrial receptivity. It provides enhanced screening for all stages of endometriosis and other conditions that interfere with implantation.
This is the first test for endometriosis with high sensitivity and specificity (96%). It is especially useful for women with unexplained IVF failure or infertility. While other tests evaluate the quality of embryos or determine optimal embryo transfer windows, only ReceptivaDx can accurately detect inflammatory conditions on the uterine lining. The results can help indicate what is likely causing implantation issues.
The test specifically identifies BCL6, a protein biomarker associated with inflammation. BCL6 is dramatically over-expressed in women with endometriosis, which makes it a likely candidate for the cause of progesterone resistance that contributes to implantation problems (read blog post).